Transformation to increase speed and redirect resources to growth opportunities within diabetes and obesity, aiming at reaching millions of untreated patients
The cGMP-4 facility will further strengthen the company's ability to serve global partners
Tourmaline Bio is a clinical-stage biopharmaceutical company developing pacibekitug, an anti-IL-6 mAb, as a treatment option for atherosclerotic cardiovascular disease
MKP11093 has shown strong results in preclinical studies with a promising safety and selectivity profile
Mansam, founded in 2022, is positioned as the first Arabian luxury fragrance brand with a vision for global expansion
New unit boosts innovation in liposomal delivery technologies with 8,500 MT capacity and export-ready production
Accelerating RNA-based therapeutic solutions for customers through co-development of products and formulation support
The facility has been designed with a dual focus on efficiency and sustainability
CGX-926 is the first clinical candidate addressing MC4R-deficient genetic obesity
Biocytogen will provide proprietary, fully human antibodies derived from its RenMice platform for evaluation in Merck’s antibody-conjugated LNP services
Subscribe To Our Newsletter & Stay Updated
